{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:03:00Z","timestamp":1792522980778,"version":"4.5.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Ponatinib is a third-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Cutaneous toxicities are a commonly reported side effect of ponatinib treatment with \u201crash\u201d being one of the most common. Specific subtypes are infrequently reported, but include hyperkeratotic, folliculocentric, ichthyosiform, and pityriasis rubra pilaris-like eruptions. Herein, we highlight the clinicopathologic features of 2 cases of ponatinib-induced pityriasis rubra pilaris-like eruptions. We also classify the clinical and histopathologic features of all previously reported ponatinib-associated eruptions in the literature and discuss treatment and potential diagnostic pitfalls.<\/jats:p>","DOI":"10.1097\/dad.0000000000002344","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T14:08:53Z","timestamp":1670594933000},"page":"64-68","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Ponatinib-Associated Cutaneous Eruptions\u2014A Case Series and Review of Clinicopathologic Findings"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-4708","authenticated-orcid":false,"given":"Isaac","family":"Weber","sequence":"first","affiliation":[{"name":"School of Medicine, University of Missouri, Columbia, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gloss","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Missouri, Columbia, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Missouri, Columbia, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Smith","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Dermatology, Michigan Medicine, Ann Arbor, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"OncoTargets Ther."},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D32310036994","article-title":"Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis","volume":"23","author":"Xu","year":"2017","journal-title":"Dermatol Online J."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/ddg.14154","article-title":"Ichthyosiform eruption and facial erythema secondary to ponatinib therapy","volume":"18","author":"Munera-Campos","year":"2020","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1111\/jdv.14368","article-title":"Ponatinib-induced widespread ichthyosiform eruption","volume":"31","author":"Derlino","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jha2.223","article-title":"Ponatinib-induced ichthyosiform eruption","volume":"2","author":"Kluger","year":"2021","journal-title":"EJHaem"},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/ijd.14853","article-title":"Ponatinib-induced lamellar ichthyosis-like eruption","volume":"59","author":"Thakur","year":"2020","journal-title":"Int J Dermatol."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"030006052090366","DOI":"10.1177\/0300060520903660","article-title":"A patient with maculopapular rash and lichenoid skin damage caused by ponatinib","volume":"48","author":"Teigen","year":"2020","journal-title":"J Int Med Res."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.13692","article-title":"Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities","volume":"173","author":"Alloo","year":"2015","journal-title":"Br J Dermatol."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/DAD.0000000000001822","article-title":"Pityriasis rubra pilaris-like reaction induced by a tyrosine kinase inhibitor, the ponatinib","volume":"43","author":"Mongereau","year":"2021","journal-title":"Am J Dermatopathol."},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jaad.2013.04.061","article-title":"Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib","volume":"69","author":"Jack","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4103\/ijdvl.IJDVL_918_19","article-title":"Ponatinib-induced atypical pityriasis rubra pilaris-like rash","volume":"86","author":"Chatterjee","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40800-017-0055-y","article-title":"Ichthyosiform pityriasis rubra pilaris-like eruption secondary to ponatinib therapy: case report and literature review","volume":"4","author":"Eber","year":"2017","journal-title":"Drug Saf Case Rep."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ced.12081","article-title":"Pityriasis rubra pilaris-like reaction induced by imatinib","volume":"38","author":"Plana","year":"2013","journal-title":"Clin Exp Dermatol."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08998280.2016.11929461","article-title":"Bevacizumab-induced pityriasis rubra pilaris-like eruption","volume":"29","author":"Brown","year":"2016","journal-title":"Baylor Univ Med Cent Proc."},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ced.14878","article-title":"Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine","volume":"47","author":"Hunjan","year":"2022","journal-title":"Clin Exp Dermatol."},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol Cancer Ther."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1101\/gad.9.18.2279","article-title":"Fyn tyrosine kinase is involved in keratinocyte differentiation control","volume":"9","author":"Calautti","year":"1995","journal-title":"Genes Dev."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:02:03Z","timestamp":1750096923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002344","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}